Understanding the Challenge of MBL Resistance
Antimicrobial resistance continues to be one of the biggest challenges in modern healthcare. Among resistant pathogens, Metallo-Beta-Lactamase (MBL)-producing bacteria are especially concerning because they can inactivate many commonly used beta-lactam antibiotics, leaving clinicians with limited treatment options.
As the number of multidrug-resistant Gram-negative infections increases worldwide, understanding MBL resistance and available treatment approaches has become increasingly important for healthcare professionals.
What Is MBL Resistance?
Metallo-Beta-Lactamases (MBLs) are enzymes produced by certain Gram-negative bacteria that can break down a wide range of beta-lactam antibiotics, including carbapenems.
Common MBL enzymes include:
- NDM (New Delhi Metallo-Beta-Lactamase)
- VIM (Verona Integron-encoded Metallo-Beta-Lactamase)
- IMP (Imipenemase)
These enzymes are frequently identified in pathogens such as:
- Klebsiella pneumoniae
- Escherichia coli
- Pseudomonas aeruginosa
- Acinetobacter baumannii
Their spread has made the management of hospital-acquired infections increasingly challenging.
Why Is MBL Resistance Difficult to Treat?
Many beta-lactam antibiotics become ineffective once exposed to MBL enzymes. Conventional beta-lactamase inhibitors also have limited activity against these enzymes, which reduces available treatment options.
Patients with MBL-producing infections may experience:
- Bloodstream infections
- Hospital-acquired pneumonia
- Complicated urinary tract infections
- Intra-abdominal infections
- Severe ICU-associated infections
Early identification of resistant organisms and appropriate antimicrobial selection are essential for effective patient management.
The Role of Aztreonam
Unlike many beta-lactam antibiotics, Aztreonam remains structurally stable against degradation by MBL enzymes.
However, many MBL-producing bacteria also produce additional beta-lactamases that can inactivate Aztreonam alone. Because of this, Aztreonam monotherapy may not always provide adequate coverage.
Why Is Avibactam Combined with Aztreonam?
Avibactam inhibits several clinically important beta-lactamases (such as Class A and some Class C and D enzymes) that may otherwise inactivate Aztreonam.
When used together, Aztreonam + Avibactam may help preserve antibacterial activity against organisms producing both MBLs and other beta-lactamases. This combination has therefore become an important area of clinical interest for managing selected multidrug-resistant Gram-negative infections.
Treatment decisions should always follow local susceptibility results, institutional guidelines, and the clinical judgment of the treating physician.
Meblanios (Aztreonam + Avibactam)
Meblanios is an Aztreonam 1500 mg + Avibactam 500 mg injectable formulation developed by AIONIOS Pharma for hospital use where this combination therapy is clinically appropriate.
Healthcare professionals should refer to approved prescribing information and institutional protocols before initiating therapy.
Clinical Situations Where This Combination May Be Considered
Depending on microbiological findings and physician assessment, Aztreonam + Avibactam may be considered in patients with:
- Complicated urinary tract infections
- Complicated intra-abdominal infections
- Hospital-acquired bacterial infections
- ICU-associated multidrug-resistant Gram-negative infections
Appropriate microbiological diagnosis and antimicrobial stewardship remain essential.
Importance of Antimicrobial Stewardship
The emergence of MBL resistance highlights the need for responsible antibiotic use.
Healthcare institutions should focus on:
- Early pathogen identification
- Culture-guided therapy
- Infection prevention measures
- Rational antibiotic prescribing
- Continuous resistance surveillance
These measures help preserve the effectiveness of available antimicrobial therapies.
Conclusion
MBL-producing Gram-negative bacteria continue to pose significant therapeutic challenges worldwide. Understanding resistance mechanisms and the clinical role of Aztreonam + Avibactam can support informed treatment decisions in appropriate hospital settings.
As research and surveillance continue to evolve, evidence-based antimicrobial stewardship and appropriate use of available therapies remain critical in addressing multidrug-resistant bacterial infections.